Osteopetrosis: Difference between revisions

From WikiMD's Wellness Encyclopedia

Deepika vegiraju (talk | contribs)
No edit summary
Tag: visualeditor-wikitext
 
No edit summary
Line 1: Line 1:
{{More citations needed|date=October 2016}}
{{Short description|Rare inherited bone disorder characterized by increased bone density}}
{{Use dmy dates|date=March 2022}}
{{Infobox medical condition (new)
{{Infobox medical condition (new)
| name           = Adult-onset osteopetrosis  (Albers-Schönberg Disease)
| name = Osteopetrosis (Albers-Schönberg Disease)
| synonyms        =
| image = Osteopetrosis pelvis X-ray.png
| image           = Osteopetrosis pelvis X-ray.png
| caption = [[X-ray]] of the [[pelvis]] showing increased bone density in osteopetrosis.
| caption         = [[X-ray]] of the [[pelvis]] of a patient with osteopetrosis, adult onset form (Albers-Schönberg disease). Note the dense appearance
| field = [[Orthopedics]], [[genetics]], [[endocrinology]]
| pronounce      =
| symptoms = Brittle bones, fractures, anemia, cranial nerve compression
| field           =  
| complications = [[Blindness]], [[deafness]], [[osteomyelitis]], [[hypocalcemia]]
| symptoms       =  
| onset = Infancy, childhood, or adulthood
| complications   =  
| types = Autosomal dominant, autosomal recessive, X-linked
| onset           =
| causes = Genetic mutations affecting osteoclast function
| duration        =  
| risks = Family history
| types           =  
| diagnosis = [[X-ray]], [[MRI]], genetic testing, bone marrow biopsy
| causes         =  
| differential = [[Osteosclerosis]], [[osteoporosis]], [[Paget’s disease]]
| risks           =  
| prevention = None known
| diagnosis       =  
| treatment = Supportive care, bone marrow transplant (severe cases)
| differential   =  
| medication = [[Calcitriol]], [[gamma interferon]], [[erythropoietin]]
| prevention     =  
| prognosis = Variable (severe forms can be life-threatening)
| treatment       =  
| frequency = 1 in 100,000 to 500,000 births (severe forms)
| medication     =  
| prognosis       =  
| frequency       =
| deaths          =  
}}
}}
'''Osteopetrosis''', literally "stone bone", also known as '''marble bone disease''' or Albers-Schönberg disease, is an extremely rare [[Biological inheritance|inherited]] [[disease|disorder]] whereby the [[bone]]s harden, becoming [[Density|dense]]r, in contrast to more prevalent conditions like [[osteoporosis]], in which the bones become less dense and more brittle, or [[osteomalacia]], in which the bones soften. Osteopetrosis can cause bones to dissolve and break.<ref>{{cite web|url=http://www.cda-adc.ca/jcda/vol-73/issue-9/839.html |title=Marble Bone Disease: A Review of Osteopetrosis and Its Oral Health Implications for Dentists |publisher=Cda-adc.ca |date= |accessdate=2013-10-17}}</ref>


It is one of the hereditary causes of  [[osteosclerosis]].<ref name="pmid18028760">{{cite journal |vauthors=Lam DK, Sándor GK, Holmes HI, Carmichael RP, Clokie CM |title=Marble bone disease: a review of osteopetrosis and its oral health implications for dentists |journal=J Can Dent Assoc |volume=73 |issue=9 |pages=839–43 |year=2007 |pmid=18028760 |doi= |url=http://www.cda-adc.ca/jcda/vol-73/issue-9/839.html}}</ref> It is considered to be the prototype of osteosclerosing dysplasias. The cause of the disease is understood to be malfunctioning [[osteoclasts]], and its inability to resorb bone. Although human osteopetrosis is a heterogeneous disorder encompassing different [[molecular lesion]]s and a range of clinical features, all forms share a single pathogenic nexus in the osteoclast. The exact molecular defects or location of the mutations taking place are unknown.<ref>{{Cite journal|last=Stark|first=Zornitza|last2=Savarirayan|first2=Ravi|date=2009-02-20|title=Osteopetrosis|journal=Orphanet Journal of Rare Diseases|volume=4|pages=5|doi=10.1186/1750-1172-4-5|issn=1750-1172|pmc=2654865|pmid=19232111}}</ref> Osteopetrosis was first described in 1903, by  German radiologist [[Heinrich Albers-Schönberg|Albers-Schönberg]].
'''Osteopetrosis''', also known as '''marble bone disease''' or '''Albers-Schönberg disease''', is a rare genetic disorder characterized by abnormally dense bones due to defective osteoclast function. Unlike [[osteoporosis]], where bones become weak and brittle, osteopetrosis leads to excess bone formation that is paradoxically fragile and prone to fractures.<ref>{{cite journal|last=Stark|first=Zornitza|last2=Savarirayan|first2=Ravi|date=2009|title=Osteopetrosis|journal=Orphanet Journal of Rare Diseases|volume=4|pages=5|doi=10.1186/1750-1172-4-5}}</ref>


<youtube>
The disease can be autosomal dominant (mild), autosomal recessive (severe, infantile), or X-linked. Osteopetrosis was first described in 1903 by the German radiologist [[Heinrich Albers-Schönberg]].
title='''{{PAGENAME}}'''
movie_url=http://www.youtube.com/v/=dxIll_6QpPo
&rel=1
embed_source_url=http://www.youtube.com/v/=dxIll_6QpPo
&rel=1
wrap = yes
width=750
height=600
</youtube>


== Symptoms ==
== Classification ==
[[File:Osteopetrosis tarda2.PNG|thumb|A 17-year-old male with osteopetrosis: Typical cranial deformity and thoracic scoliosis]]
Osteopetrosis is classified based on genetic inheritance and severity:
Despite this excess bone formation, people with osteopetrosis tend to have bones that are more brittle than normal. Mild osteopetrosis may cause no symptoms, and present no problems.<ref name=":2">{{Cite web|url=http://www.checkorphan.org/diseases/albers-schonberg-disease|title=Albers-Schonberg disease — CheckOrphan|website=www.checkorphan.org|language=en|access-date=2017-12-13}}</ref>


However, serious forms can result in...<ref name=":2"/>
* Autosomal Dominant Osteopetrosis (ADO) (Adult-onset, Albers-Schönberg Disease)
* [[Stunted growth]], deformity, and increased likelihood of fractures
* Milder form
* Patients suffer anemia, recurrent infections, and [[hepatosplenomegaly]] due to bone expansion leading to bone marrow narrowing and [[extramedullary hematopoiesis]]
* Usually asymptomatic or diagnosed after fractures
* It can also result in [[blindness]], [[Facial nerve paralysis|facial paralysis]], and [[Hearing loss|deafness]], due to the increased pressure put on the nerves by the extra bone
* Affects 1 in 20,000 people
* Abnormal cortical bone [[morphology (biology)|morphology]]
* Abnormal form of the [[vertebral bodies]]
* Abnormality of [[Thermoregulation|temperature regulation]]
* Abnormality of the ribs
* Abnormality of vertebral [[epiphysis]] morphology
* [[Bone pain]]
* [[Cranial nerves|Cranial nerve]] [[paralysis]]
* [[Craniosynostosis]]
* [[Hearing loss|Hearing impairment]]
* [[Hypocalcaemia|Hypocalcemia]]
{{Bone pathology}}


===Malignant infantile osteopetrosis===
* Autosomal Recessive Osteopetrosis (ARO) (Malignant Infantile Osteopetrosis)
[[File:Autosomal recessive - en.svg|thumb]]
* Severe, early-onset form
Autosomal recessive osteopetrosis (ARO), also known as [[malignant infantile osteopetrosis]], is a rare type of skeletal dysplasia characterized by a distinct radiographic pattern of overall increased density of the bones with fundamental involvement of the medullary portion. Infantile osteopetrosis typically manifests in infancy. Diagnosis is principally based on clinical and radiographic evaluation, confirmed by gene analysis where applicable.<ref name="elsobky2016" />  As a result of medullary canal obliteration and bony expansion, grave [[pancytopenia]], cranial nerve compression, and pathologic fractures may ensue.  The [[prognosis]] is poor if untreated. The classic [[Radiography|radiographic]] features include, endobone or "bone-within-bone" appearance in the spine, pelvis and proximal femora, upper limbs, and short tubular bones of the hand. Additionally, there is the [[Erlenmeyer flask deformity]] type 2 which is characterized by absence of normal diaphysial metaphysical modeling of the distal femora with abnormal radiographic appearance of trabecular bone and alternating radiolucent metaphyseal bands.<ref name="elsobky2016">Elsobky TA, Elsobky E, Sadek I, Elsayed SM, Khattab MF (2016). [http://www.sciencedirect.com/science/article/pii/S2352187215300243 "A case of infantile osteopetrosis: The radioclinical features with literature update"]. ''Bone Rep''. '''4''':11-16. http://doi.org/10.1016/j.bonr.2015.11.002. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926827/ PMC4926827]. {{PMID|28326337}}</ref>
* Fatal if untreated due to bone marrow failure
* Requires bone marrow transplant


The precise and early diagnosis of infantile osteopetrosis is important for management of complications, genetic counselling, and timely institution of appropriate treatment, namely [[hematopoietic stem cell transplantation]] (HSCT), which offers a satisfactory treatment modality for a considerable percentage of infantile osteopetrosis.<ref>Orchard PJ, Fasth AL, Le Rademacher J, He W, Boelens JJ, Horwitz EM, et al (2015). "Hematopoietic stem cell transplantation for infantile osteopetrosis." ''Blood''. '''126''':270–6. {{doi|10.1182/blood-2015-01-625541}}. {{PMID|26012570}}.</ref> Amelioration of radiographic bone lesions after HSCT in infantile osteopetrosis has been proposed as an important indicator of success of the therapy. A few publications with limited study participants have demonstrated the resolution of skeletal radiographic pathology following HSCT.<ref name="elsobky2017">Elsobky TA, El-Haddad A, Elsobky E, Elsayed SM, Sakr HM (2017). [http://www.sciencedirect.com/science/article/pii/S0378603X1630242X "Reversal of skeletal radiographic pathology in a case of malignant infantile osteopetrosis following hematopoietic stem cell transplantation"]. ''Egypt J Radiol Nucl Med''. '''48''' (1):237–43. http://doi.org/10.1016/j.ejrnm.2016.12.013.</ref><ref name="Hashemi2015">Hashemi Taheri AP, Radmard AR, Kooraki S, Behfar M, Pak N, Hamidieh AA, et al (2015). "Radiologic resolution of malignant infantile osteopetrosis skeletal changes following hematopoietic stem cell transplantation." ''Pediatr Blood Cancer''. '''62''':1645–9. {{doi|10.1002/pbc.25524}}. {{PMID|25820806}}</ref>
* X-linked Osteopetrosis
[[File:Autosomal dominant - en.svg|thumb]]
* Extremely rare
* Associated with immune deficiencies and severe osteopetrosis


=== Adult osteopetrosis ===
== Symptoms ==
Autosomal dominant osteopetrosis (ADO) is also known as [[Albers-Schonberg disease]]. Most do not know they have this disorder because most individuals do not show any symptoms. However, the ones that do show symptoms will typically have a curvature of the spine ([[scoliosis]]), and multiple bone fractures. There are two types of adult osteopetrosis based on the basis of radiographic, biochemical, and clinical features.
Despite increased bone density, affected individuals may suffer from brittle bones and fractures. Symptoms vary based on severity:
{| class="wikitable"
!Characteristic
!Type I
!Type II
|-
|Skull Sclerosis
|Marked sclerosis mainly of the vault
|Sclerosis mainly of the base
|-
|Spine
|Does not show signs of sclerosis
|Shows the rugger-jersey appearance
|-
|Pelvis
|No endobones
|Shows endobones in the pelvis
|-
|Risk of Fracture
|Low
|High
|-
|Serum Acid Phosphate
|Normal
|Very high
|}
Many patients will have bone pains. The defects are very common and include neuropathies due to cranial [[Nerve compression syndrome|nerve entrapment]], [[osteoarthritis]], and carpal tunnel syndrome. About 40% of patients will experience recurrent fractures of their bones. 10% of patients will have [[osteomyelitis]] of the [[mandible]].


== Causes ==
* Skeletal abnormalities:
The various types of osteopetrosis are caused by genetic changes (mutations) in one of at least ten genes. There is nothing a parent can do before, during or after a pregnancy to cause osteopetrosis in a child.<ref name=":2"/>
* Stunted growth, scoliosis, bone deformities
* Frequent fractures despite dense bones
* Craniosynostosis (premature skull closure)


The genes associated with osteopetrosis are involved in the development and/or function of osteoclasts, cells that break down bone tissue when old bone is being replaced by new bone (bone remodeling). This process is necessary to keep bones strong and healthy. Mutations in these genes can lead to abnormal [[osteoclast]]s, or having too few [[osteoclast]]s. If this happens, old bone cannot be broken down as new bone is formed, so bones become too dense and prone to breaking.<ref name=":2" />
* Neurological complications:
* Mutations in the [[CLCN7]] gene cause most cases of autosomal dominant osteopetrosis, 10-15% of cases of [[Autosomal Recessive|autosomal recessive]] osteopetrosis (the most severe form), and all known cases of intermediate autosomal osteopetrosis.
* Blindness (optic nerve compression)
* Mutations in the [[TCIRG1]] gene cause about 50% of cases of [[Autosomal Recessive|autosomal recessive]] osteopetrosis.
* Deafness (auditory nerve compression)
* Mutations in the [[IKBKG]] gene cause [[X-linked]] osteopetrosis.
* Facial paralysis (cranial nerve compression)
* Mutations in other genes are less common causes of osteopetrosis.
* In about 30% percent of affected people, the cause is unknown.
Normally, bone growth is a balance between osteoblasts (cells that create bone tissue) and osteoclasts (cells that destroy bone tissue). Sufferers of osteopetrosis have a deficiency of osteoclasts, meaning too little bone is being resorbed, resulting in too much bone being created.


=== Gene variation ===
* Bone marrow failure:
{| class="wikitable"
* Anemia
|-
* Recurrent infections due to low white blood cells
! Name
* Hepatosplenomegaly (enlarged liver/spleen due to extramedullary hematopoiesis)
! [[OMIM]]
! Gene
|-
| OPTA1
| {{OMIM2|607634}}
| ''[[LRP5]]'' receptor
|-
| OPTA2
| {{OMIM2|166600}}
| ''[[CLCN7]]'' chloride channel
|-
| OPTB1
| {{OMIM2|259700}}
| ''[[TCIRG1]]'' ATPase
|-
| OPTB2
| {{OMIM2|259710}}
| ''[[RANKL]]''
|-
| OPTB3
| {{OMIM2|259730}}
| ''[[Carbonic anhydrase II|CA2]]'' ([[renal tubular acidosis]])
|-
| OPTB4
| {{OMIM2|611490}}
| ''CLCN7'' chloride channel
|-
| OPTB5
| {{OMIM2|259720}}
| ''[[OSTM1]]'' [[ubiquitin]] ligase
|-
| OPTB6
| {{OMIM2|611497}}
| ''[[PLEKHM1]]'' [[Signal transducing adaptor protein|adapter protein]]
|-
| OPTB7
| {{OMIM2|612301}}
| ''[[TNFRSF11A]]'' (RANK receptor)
|}


== Mechanisms ==
* Metabolic disturbances:
Normal bone growth is achieved by a balance between bone formation by [[osteoblasts]] and bone resorption (breakdown of bone matrix) by [[osteoclasts]].<ref>{{cite book|title=Basic and Applied Bone Biology|last1=Allen|first1=Matthew R.|last2=Burr|first2=David B.|date=2014|publisher=Academic Press|isbn=9780124160156|location=San diego|pages=75–90|accessdate=}}</ref> In osteopetrosis, the number of osteoclasts may be reduced, normal, or increased. Most importantly, osteoclast dysfunction mediates the pathogenesis of this disease.<ref>{{cite journal|last1=Memet|first1=Aker|last2=Rouvinski|first2=Alex|last3=Hshavia|first3=Saar|last4=Ta-Shma|first4=Asaf|last5=Shaag|first5=Avraham|last6=Zenvirt|first6=Shamir|last7=Israel|first7=Shoshana|last8=Weintraub|first8=Michael|last9=Taraboulos|first9=Albert|date=April 2012|title=An SNX10 mutation causes malignant osteoporosis of infancy|url=http://jmg.bmj.com/content/49/4/221.long|journal=Journal of Medical Genetics|volume=49|issue=4|pages=221–6|doi=10.1136/jmedgenet-2011-100520|pmid=22499339|accessdate=August 19, 2016|last10=Bar-Shavit|first10=Zvi|last11=Elpeleg|first11=Orly}}</ref>
* Hypocalcemia (low calcium)
* Delayed tooth eruption
* Increased risk of osteomyelitis (bone infections)


Osteopetrosis is caused by underlying mutations that interfere with the acidification of the [[osteoclast]] resorption pit, for example due to a deficiency of the [[carbonic anhydrase]] enzyme encoded by the [[Carbonic anhydrase II|CA2]] gene.<ref>Askmyr MK et al.: Towards a better understanding and new therapeutics of osteopetrosis. Br J Haematol 140:597, 208</ref> [[Carbonic anhydrase]] is required by osteoclasts for proton production. Without this enzyme hydrogen ion pumping is inhibited and bone resorption by osteoclasts is defective, as an acidic environment is needed to dissociate [[calcium hydroxyapatite]] from the bone matrix. As bone resorption fails while bone formation continues, excessive bone is formed.<ref>Robbins Basic Pathology by Kumar, Abbas, Fausto, and Mitchell, 8th edition</ref>
== Diagnosis ==
Diagnosis is based on radiographic imaging, genetic testing, and laboratory findings:


Mutations in at least nine genes cause the various types of osteopetrosis. Mutations in the ''[[CLCN7]]'' gene are responsible for about 75 percent of cases of [[autosomal dominant]] osteopetrosis, 10 to 15 percent of cases of autosomal recessive osteopetrosis, and all known cases of intermediate autosomal osteopetrosis. ''[[TCIRG1]]'' gene mutations cause about 50 percent of cases of autosomal recessive osteopetrosis. Mutations in other genes are less common causes of autosomal dominant and autosomal recessive forms of the disorder. The [[X-linked]] type of osteopetrosis, OL-EDA-ID, results from mutations in the ''[[IKBKG]]'' gene. In about 30 percent of all cases of osteopetrosis, the cause of the condition is unknown.<ref name=":0">{{Cite web|url=https://ghr.nlm.nih.gov/condition/osteopetrosis#|title=osteopetrosis|last=Reference|first=Genetics Home|website=Genetics Home Reference|language=en|access-date=2017-12-13}}</ref>
* X-rays – Classic "bone-in-bone" (endobone) pattern, Erlenmeyer flask deformity in long bones
* MRI/CT scans – To assess nerve compression
* Genetic testing – Identifies mutations in CLCN7, TCIRG1, RANKL, OSTM1, CA2 genes
* Bone marrow biopsy – Evaluates bone marrow failure in infantile osteopetrosis


The genes associated with osteopetrosis are involved in the formation, development, and function of specialized cells called [[osteoclast]]s. These cells break down bone tissue during bone remodeling, a normal process in which old bone is removed and new bone is created to replace it. Bones are constantly being remodeled, and the process is carefully controlled to ensure that bones stay strong and healthy.<ref name=":0" />
== Treatment ==
Treatment depends on severity:


Mutations in any of the genes associated with osteopetrosis lead to abnormal or missing [[osteoclast]]s. Without functional osteoclasts, old bone is not broken down as new bone is formed. As a result, bones throughout the skeleton become unusually dense. The bones are also structurally abnormal, making them prone to fracture. These problems with bone remodeling underlie all of the major features of osteopetrosis.<ref name=":0" />[[File:Protein TNFSF11 PDB 1s55.png|thumb|Protein TNFSF 11(RANKL)]]
1. Bone Marrow Transplantation (BMT)
* Curative for infantile osteopetrosis
* Replaces defective osteoclast precursors with healthy donor cells
* Most effective before irreversible complications develop


==Diagnosis==
2. Medications
The differential diagnosis of osteopetrosis includes other disorders that produce [[osteosclerosis]]. They constitute a wide array of disorders with clinically and radiologically diverse manifestations. Among the differential diagnosis are hereditary ostoesclerosing dysplasias such as; neuropathic infantile osteopetrosis, infantile osteopetrosis with renal tubular acidosis, infantile osteopetrosis with immunodeficiency, infantile osteopetrosis with leukocyte adhesion deficiency syndrome (LAD-III), [[pyknodysostosis]] (osteopetrosis acro-osteolytica), [[osteopoikilosis]] ([[Buschke–Ollendorff syndrome]]), [[osteopathia striata]] with cranial sclerosis, mixed sclerosing [[skeletal dysplasia]]s, progressive diaphyseal dysplasia ([[Camurati–Engelmann disease]]), SOST-related sclerosing [[skeletal dysplasia]]s.<ref name="elsobky2016" /> Besides, the differential diagnosis includes acquired conditions that induce osteosclerosis such as osteosclerotic metastasis notably carcinomas of the prostate gland and breast, [[Paget's disease of bone]], myelofibrosis (primary disorder or secondary to intoxication or malignancy), Erdheim-Chester disease, osteosclerosing types of [[osteomyelitis]], [[sickle cell disease]], hypervitaminosis D, and [[hypoparathyroidism]].<ref name="Ihde">Ihde LL, Forrester DM, Gottsegen CJ, Masih S, Patel DB, Vachon LA, et al. (2011). [http://pubs.rsna.org/doi/10.1148/rg.317115093 "Sclerosing bone dysplasias: Review and differentiation from other causes of osteosclerosis"]. ''RadioGraphics''. '''31''':7, 1865-82. DOI: https://dx.doi.org/10.1148/rg.317115093</ref>
* Calcitriol (Vitamin D3) – Activates dormant osteoclasts to promote bone resorption
* Gamma interferon – Reduces bone density, improves immune function
* Erythropoietin – Treats anemia
* Corticosteroids – Stimulate bone resorption, reduce inflammation


== Treatment  ==
3. Supportive Care
It was the 1st genetic disease treated with hematopoietic stem cell transplantation (Osteoclasts are derived from hematopoietic precursors). There is no cure, although curative therapy with [[bone marrow]] transplantion is being investigated in clinical trials. It is believed the healthy marrow will provide the sufferer with cells from which osteoclasts will develop.<ref name=":2" /> If complications occur in children, patients can be treated with [[vitamin D]]. Gamma interferon has also been shown to be effective, and it can be associated to vitamin D. [[Erythropoietin|Erythropoetin]] has been used to treat any associated [[anemia]]. [[Corticosteroid]]s may alleviate both the anemia and stimulate bone resorption. Fractures and [[osteomyelitis]] can be treated as usual.<ref name=":2" /> Treatment for osteopetrosis depends on the specific symptoms present and the severity in each person. Therefore, treatment options must be evaluated on an individual basis. Nutritional support is important to improve growth and it also enhances responsiveness to other treatment options. A [[Calcium deficiency (plant disorder)|calcium-deficient]] diet has been beneficial for some affected people.<ref name=":2" />
* Orthopedic management – Fracture treatment, surgical correction of deformities
* Hearing/vision aids – If cranial nerves are affected
* Dental care – Prevention of osteomyelitis (bone infections)


Treatment is necessary for the infantile form:<ref name=":2" />
== Prognosis ==
* Vitamin D ([[calcitriol]]) appears to stimulate dormant osteoclasts, which stimulates bone resorption
The prognosis depends on disease type:
* Gamma interferon can have long-term benefits. It improves [[white blood cell]] function (leading to fewer infections), decreases bone volume, and increases bone marrow volume.
* Infantile osteopetrosis (ARO) – Fatal if untreated, but curable with bone marrow transplantation
* [[Erythropoietin]] can be used for anemia, and [[corticosteroid]]s can be used for anemia and to stimulate bone resorption.
* Adult-onset osteopetrosis (ADO) – Normal life expectancy, but fracture risk remains high
[[Bone marrow transplantation]] (BMT) improves some cases of severe, infantile osteopetrosis associated with bone marrow failure, and offers the best chance of longer-term survival for individuals with this type.<ref name=":2" />
 
In pediatric (childhood) osteopetrosis, surgery is sometimes needed because of fractures. Adult osteopetrosis typically does not require treatment, but complications of the condition may require intervention. Surgery may be needed for [[Aesthetics|aesthetic]] or functional reasons (such as multiple fractures, deformity, and loss of function), or for severe degenerative joint disease.<ref name=":2" />
==Prognosis==
The long-term-outlook for people with osteopetrosis depends on the subtype and the severity of the condition in each person. The severe infantile forms of osteopetrosis are associated with shortened life expectancy, with most untreated children not surviving past their first decade. [[Bone marrow transplantation]] seems to have cured some infants with early-onset disease. However, the long-term prognosis after transplantation is unknown. For those with onset in childhood or adolescence, the effect of the condition depends on the specific symptoms (including how fragile the bones are and how much pain is present). Life expectancy in the adult-onset forms is normal.<ref>{{Cite web|url=https://rarediseases.info.nih.gov/diseases/4155/osteopetrosis|title=Osteopetrosis {{!}} Genetic and Rare Diseases Information Center (GARD) – an NCATS Program|website=rarediseases.info.nih.gov|language=en|access-date=2017-12-13}}</ref>


== Prevalence ==
== Prevalence ==
Approximately eight to 40 children are born in the United States each year with the malignant infantile type of osteopetrosis. One in every 100,000 to 500,000 individuals is born with this form of osteopetrosis. Higher rates have been found in Denmark and Costa Rica. Males and females are affected in equal numbers.<ref name=":3">{{Cite news|url=https://rarediseases.org/rare-diseases/osteopetrosis/|title=Osteopetrosis - NORD (National Organization for Rare Disorders)|work=NORD (National Organization for Rare Disorders)|access-date=2017-12-13|language=en-US}}</ref>
* Severe (infantile) osteopetrosis – 1 in 100,000–500,000 births
* Mild (adult-onset) osteopetrosis – 1 in 20,000 individuals
* Higher prevalence in certain populations (e.g., Costa Rica, Denmark, Brazil)


The adult type of osteopetrosis affects about 1,250 individuals in the United States. One in every 200,000 individuals is affected by the adult type of osteopetrosis. Higher rates have been found in Brazil. Males and females are affected in equal numbers.<ref name=":3" />
== Recent Research ==
New therapies are being explored:
* Gene therapy – Potential to correct defective osteoclast function
* RANKL administration – Improves osteoclast activity in RANKL-deficient patients<ref>{{Cite journal|last=Lo Iacono|first=Nadia|title=Osteopetrosis rescue upon RANKL administration|journal=Journal of Bone and Mineral Research|date=2012|doi=10.1002/jbmr.1712}}</ref>


== Recent research ==
== Notable Cases ==
* Gene replacement therapy: [https://www.ncbi.nlm.nih.gov/pubmed/22836362 Osteopetrosis rescue up RANKL administration to RANKL (-/-) mice: a new therapy for human RANKL-dependent ARO.]
* Laurel Burch – American artist with severe osteopetrosis<ref>{{cite news |url=https://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2007/09/23/BAH2S9B1N.DTL |title=Marin County artist Laurel Burch dead at 61 of rare bone disease}}</ref>
** Findings: They demonstrated that the systematic administration of RANKL for 1 month to Rankl(-/-) mice, which closely resemble the human disease, significantly improved the bone phenotype and has beneficial effects on bone marrow, spleen and thymus; major adverse effects arise only when mice are clearly overtreated. Overall, it provide evidence that the pharmacological administration of RANKL represents the appropriate treatment option for RANKL-deficient ARO patients, to be validated in a pilot clinical trial.<ref>{{Cite journal|last=Lo Iacono|first=Nadia|last2=Blair|first2=Harry C.|last3=Poliani|first3=Pietro L.|last4=Marrella|first4=Veronica|last5=Ficara|first5=Francesca|last6=Cassani|first6=Barbara|last7=Facchetti|first7=Fabio|last8=Fontana|first8=Elena|last9=Guerrini|first9=Matteo M.|date=December 2012|title=Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice: a new therapy for human RANKL-dependent ARO|journal=Journal of Bone and Mineral Research|volume=27|issue=12|pages=2501–2510|doi=10.1002/jbmr.1712|issn=1523-4681|pmid=22836362}}</ref>
* Lil Bub – Internet-famous cat with osteopetrosis
The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition. [https://rarediseases.info.nih.gov/diseases/fda-orphan-drugs Learn more orphan products.]
* '''Interferon gamma-1b''' '''(Brand name: [https://www.actimmune.com Actimmune®])''' - Manufactured by InterMune, Inc. FDA-approved indication: Delaying time to disease progression in patients with severe, malignant osteopetrosis. [https://druginfo.nlm.nih.gov/drugportal/name/Actimmune National Library of Medicine Drug Information Portal]


==Notable cases==
== See Also ==
* [[Laurel Burch]]<ref name="titleMarin County artist Laurel Burch dead at 61 of rare bone disease">{{cite news |url=http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2007/09/23/BAH2S9B1N.DTL |title=Marin County artist Laurel Burch dead at 61 of rare bone disease |accessdate=2007-12-23 |work=The San Francisco Chronicle | first=Heather | last=Maddan |date=2007-09-23}}</ref>
* [[Paget’s disease of bone]]
*[[Lil Bub]]
* [[Osteoporosis]]
* [[Skeletal dysplasia]]


==References==
== References ==
{{Reflist}}
{{Reflist}}


==Further reading==
== External Links ==
*[https://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=clcn7  GeneReviews/NCBI/NIH/UW entry on CLCN7-Related Osteopetrosis]
 
== External links ==
{{Medical resources
{{Medical resources
| DiseasesDB     = 9377  
| DiseasesDB = 9377
| ICD10         = {{ICD10|Q|78|2|q|65}}  
| ICD10 = {{ICD10|Q|78|2|q|65}}
| ICD9           = {{ICD9|756.52}}  
| ICD9 = {{ICD9|756.52}}
| ICDO          = 
| OMIM = 166600
OMIM           = 166600  
| MedlinePlus =
| OMIM_mult      = {{OMIM2|259700}}
| eMedicineSubj = med
MedlinePlus   =
| eMedicineTopic = 1692
| eMedicineSubj = med  
| MeshID = D010022
| eMedicineTopic = 1692  
| MeshID         = D010022
}}
}}
{{Osteochondrodysplasia}}
{{Osteochondrodysplasia}}
{{Cell surface receptor deficiencies}}
{{Cell surface receptor deficiencies}}
{{ATPase disorders}}
{{ATPase disorders}}
{{Channelopathy}}
{Channelopathy}}
 
{{stub}}
[[Category:Genetic disorders by system]]
[[Category:Genetic disorders by system]]
[[Category:Rare diseases]]
[[Category:Rare diseases]]

Revision as of 01:49, 20 March 2025

Rare inherited bone disorder characterized by increased bone density



Osteopetrosis (Albers-Schönberg Disease)
Synonyms N/A
Pronounce N/A
Field Orthopedics, genetics, endocrinology
Symptoms Brittle bones, fractures, anemia, cranial nerve compression
Complications Blindness, deafness, osteomyelitis, hypocalcemia
Onset Infancy, childhood, or adulthood
Duration N/A
Types Autosomal dominant, autosomal recessive, X-linked
Causes Genetic mutations affecting osteoclast function
Risks Family history
Diagnosis X-ray, MRI, genetic testing, bone marrow biopsy
Differential diagnosis Osteosclerosis, osteoporosis, Paget’s disease
Prevention None known
Treatment Supportive care, bone marrow transplant (severe cases)
Medication Calcitriol, gamma interferon, erythropoietin
Prognosis Variable (severe forms can be life-threatening)
Frequency 1 in 100,000 to 500,000 births (severe forms)
Deaths N/A


Osteopetrosis, also known as marble bone disease or Albers-Schönberg disease, is a rare genetic disorder characterized by abnormally dense bones due to defective osteoclast function. Unlike osteoporosis, where bones become weak and brittle, osteopetrosis leads to excess bone formation that is paradoxically fragile and prone to fractures.<ref>Stark, Zornitza,

 Osteopetrosis, 
 Orphanet Journal of Rare Diseases, 
 
 Vol. 4,
 pp. 5,
 DOI: 10.1186/1750-1172-4-5,</ref>

The disease can be autosomal dominant (mild), autosomal recessive (severe, infantile), or X-linked. Osteopetrosis was first described in 1903 by the German radiologist Heinrich Albers-Schönberg.

Classification

Osteopetrosis is classified based on genetic inheritance and severity:

  • Autosomal Dominant Osteopetrosis (ADO) (Adult-onset, Albers-Schönberg Disease)
  • Milder form
  • Usually asymptomatic or diagnosed after fractures
  • Affects 1 in 20,000 people
  • Autosomal Recessive Osteopetrosis (ARO) (Malignant Infantile Osteopetrosis)
  • Severe, early-onset form
  • Fatal if untreated due to bone marrow failure
  • Requires bone marrow transplant
  • X-linked Osteopetrosis
  • Extremely rare
  • Associated with immune deficiencies and severe osteopetrosis

Symptoms

Despite increased bone density, affected individuals may suffer from brittle bones and fractures. Symptoms vary based on severity:

  • Skeletal abnormalities:
  • Stunted growth, scoliosis, bone deformities
  • Frequent fractures despite dense bones
  • Craniosynostosis (premature skull closure)
  • Neurological complications:
  • Blindness (optic nerve compression)
  • Deafness (auditory nerve compression)
  • Facial paralysis (cranial nerve compression)
  • Bone marrow failure:
  • Anemia
  • Recurrent infections due to low white blood cells
  • Hepatosplenomegaly (enlarged liver/spleen due to extramedullary hematopoiesis)
  • Metabolic disturbances:
  • Hypocalcemia (low calcium)
  • Delayed tooth eruption
  • Increased risk of osteomyelitis (bone infections)

Diagnosis

Diagnosis is based on radiographic imaging, genetic testing, and laboratory findings:

  • X-rays – Classic "bone-in-bone" (endobone) pattern, Erlenmeyer flask deformity in long bones
  • MRI/CT scans – To assess nerve compression
  • Genetic testing – Identifies mutations in CLCN7, TCIRG1, RANKL, OSTM1, CA2 genes
  • Bone marrow biopsy – Evaluates bone marrow failure in infantile osteopetrosis

Treatment

Treatment depends on severity:

1. Bone Marrow Transplantation (BMT)

  • Curative for infantile osteopetrosis
  • Replaces defective osteoclast precursors with healthy donor cells
  • Most effective before irreversible complications develop

2. Medications

  • Calcitriol (Vitamin D3) – Activates dormant osteoclasts to promote bone resorption
  • Gamma interferon – Reduces bone density, improves immune function
  • Erythropoietin – Treats anemia
  • Corticosteroids – Stimulate bone resorption, reduce inflammation

3. Supportive Care

  • Orthopedic management – Fracture treatment, surgical correction of deformities
  • Hearing/vision aids – If cranial nerves are affected
  • Dental care – Prevention of osteomyelitis (bone infections)

Prognosis

The prognosis depends on disease type:

  • Infantile osteopetrosis (ARO) – Fatal if untreated, but curable with bone marrow transplantation
  • Adult-onset osteopetrosis (ADO) – Normal life expectancy, but fracture risk remains high

Prevalence

  • Severe (infantile) osteopetrosis – 1 in 100,000–500,000 births
  • Mild (adult-onset) osteopetrosis – 1 in 20,000 individuals
  • Higher prevalence in certain populations (e.g., Costa Rica, Denmark, Brazil)

Recent Research

New therapies are being explored:

  • Gene therapy – Potential to correct defective osteoclast function
  • RANKL administration – Improves osteoclast activity in RANKL-deficient patients<ref>Lo Iacono, Nadia,
 Osteopetrosis rescue upon RANKL administration, 
 Journal of Bone and Mineral Research, 
 
 
 
 DOI: 10.1002/jbmr.1712,</ref>

Notable Cases

  • Laurel Burch – American artist with severe osteopetrosis<ref>

,

 Marin County artist Laurel Burch dead at 61 of rare bone disease Full text, 
 ,

</ref>

  • Lil Bub – Internet-famous cat with osteopetrosis

See Also

References

<references group="" responsive="1"></references>


External Links





{Channelopathy}}

This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia